Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

- PMLiVE

Genzyme cuts staff and signs $845m gene therapy pact

Alliance with Voyager Therapeutics revealed on the same day as job losses

Sanofi reception

Leaderless Sanofi sees strong growth

French firm confirms it will seek a new CEO this quarter

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

Novo Nordisk’s Xultophy debuts in Switzerland

It is the first market for combination of diabetes treatments Tresiba and Victoza

Sanofi reception

Monthly dosing effective for Sanofi’s alirocumab

New data puts pressure on Amgen's evolocumab

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links